Needham Reiterates Buy on ACADIA Pharmaceuticals, Maintains $41 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 90.9%

Neg 0% Neu 90.9% Pos 0%

Needham analyst Ami Fadia reiterates ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Buy and maintains $41 price target.

Comments

No comments yet. Be the first!